SCHEMBL29487533

SCHEMBL29487533

O=C1C(=O)N(Cc2ccc(Cl)c(Cl)c2)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 1.00
CES1 P23141 5/20 1.00
APAF1 O14727 3/20 1.00
BCHE P06276 3/20 1.00
ACHE P22303 2/20 1.00
TP53 P04637 1/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
MAPT P10636 1/20 1.00
ALOX15 P16050 1/20 1.00
TSHR P16473 1/20 1.00
ALOX12 P18054 1/20 1.00
HSD17B10 Q99714 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
CES2 O00748 1/20 0.73
ALDH3A1 P30838 6/20 0.69
CHRM1 P11229 3/20 0.69
ALDH2 P05091 2/20 0.69
CHRM5 P08912 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30081910 1.00 ALDH1A1 (1.00) ALDH1A1CES1APAF1BCHEACHE
SCHEMBL5426477 1.00 ALDH1A1 (1.00) ALDH1A1CES1APAF1BCHEACHE
SCHEMBL18288159 0.87 CES1 (0.90) ALDH1A1CES1APAF1BCHEACHE
SCHEMBL22177086 0.87 ALDH1A1 (0.78) ALDH1A1CES1APAF1BCHEACHE
SCHEMBL3027106 0.84 CES1 (1.00) ALDH1A1CES1APAF1BCHEACHE
SCHEMBL24270334 0.84 APAF1 (0.80) ALDH1A1CES1APAF1BCHEACHE
SCHEMBL10955382 0.84 ALDH1A1 (0.72) ALDH1A1CES1APAF1BCHEACHE
SCHEMBL4727488 0.84 ALDH1A1 (0.72) ALDH1A1CES1APAF1BCHEACHE
SCHEMBL18668985 0.83 ALDH1A1 (0.70) ALDH1A1CES1APAF1BCHEACHE
SCHEMBL29506660 0.82 ALDH1A1 (1.00) ALDH1A1CES1APAF1BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014090-A1 NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING UNIV GEORGIA (US) 2026-01-15 US disclosed
US-12521354-B2 Nanoparticles for targeted non-surgical spaying and neutering UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2026-01-13 US disclosed
US-20250288532-A1 NANOPARTICLES FOR TREATING PROSTATE CANCER UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2025-09-18 US disclosed
EP-3600254-B1 CORNEA EPITHELIUM CELL DERIVED VESICLES CONTAINING P53 FOR CANCER THERAPY EXOPROTHER MEDICAL LTD (IL) 2025-09-03 EP disclosed
US-12350384-B2 Nanoparticles for treating prostate cancer UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2025-07-08 US disclosed
EP-3525791-B1 USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING TECHNION RES & DEV FOUNDATION (IL) 2025-05-21 EP disclosed
US-20250144038-A1 NANOPARTICLES FOR PREVENTING PERI/POST-MENOPAUSAL BONE LOSS AND/OR OBESITY UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2025-05-08 US disclosed
US-12214085-B2 Nanoparticles for preventing peri/post-menopausal bone loss and/or obesity UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2025-02-04 US disclosed
CN-119302956-A Application of shikonin combined with octenib in reversing octenib drug-resistant non-small cell lung cancer 广东医科大学附属医院 2025-01-14 CN disclosed
CN-119278052-A Preventing or alleviating adverse reactions associated with T cell cements 豪夫迈·罗氏有限公司 2025-01-07 CN disclosed
WO-2022261213-A1 NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2022-12-15 WO disclosed
WO-2022261186-A1 NANOPARTICLES FOR PREVENTING PERI/POST-MENOPAUSAL BONE LOSS AND/OR OBESITY UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2022-12-15 WO disclosed
US-20220387336-A1 NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2022-12-08 US disclosed
US-20220387334-A1 NANOPARTICLES FOR PREVENTING PERI/POST-MENOPAUSAL BONE LOSS AND/OR OBESITY UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2022-12-08 US disclosed
US-20220387335-A1 NANOPARTICLES FOR TREATING PROSTATE CANCER UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2022-12-08 US disclosed
US-20220323406-A1 METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-10-13 US disclosed
CN-114652851-A Antibody conjugate of anti-TROP2 protein 石药集团巨石生物制药有限公司 2022-06-24 CN disclosed
WO-2022104258-A1 COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT AND TREATMENT OF CANCER PATIENT AMBAY IMMUNE SENSORS AND CONTROLS, LLC/AMBAY (US) 2022-05-19 WO disclosed
US-11324827-B2 Multifunctionalized polyethylene glycol derivative and preparation method therefor XIAMEN SINOPEG BIOTECH CO., LTD. (CN) 2022-05-10 US disclosed
US-11291705-B2 Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2022-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220387335-A1 NANOPARTICLES FOR TREATING PROSTATE CANCER FSHR, GNRHR, AR ALDH1A1 4313/4885CES1 4192/4885APAF1 35/4885
US-20260014090-A1 NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING FSHR, GNRHR, LHCGR ALDH1A1 4648/4885CES1 3399/4885APAF1 44/4885
US-20250144038-A1 NANOPARTICLES FOR PREVENTING PERI/POST-MENOPAUSAL BONE LOSS AND/OR OBESITY MORF4L1, POF1B, GNRHR ALDH1A1 4864/4885CES1 3345/4885APAF1 22/4885
US-20250288532-A1 NANOPARTICLES FOR TREATING PROSTATE CANCER FSHR, GNRHR, AR ALDH1A1 4313/4885CES1 4192/4885APAF1 35/4885
US-20220387336-A1 NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING NXF1, POF1B, ASF1A ALDH1A1 4309/4885CES1 3830/4885APAF1 15/4885
US-12214085-B2 Nanoparticles for preventing peri/post-menopausal bone loss and/or obesity MORF4L1, POF1B, GNRHR ALDH1A1 4864/4885CES1 3345/4885APAF1 22/4885
US-12350384-B2 Nanoparticles for treating prostate cancer FSHR, GNRHR, AR ALDH1A1 4313/4885CES1 4192/4885APAF1 35/4885
US-11324827-B2 Multifunctionalized polyethylene glycol derivative and preparation method therefor HDGF, F11, F12 ALDH1A1 1582/4885CES1 1127/4885APAF1 2793/4885
US-20220387334-A1 NANOPARTICLES FOR PREVENTING PERI/POST-MENOPAUSAL BONE LOSS AND/OR OBESITY MORF4L1, POF1B, GNRHR ALDH1A1 4864/4885CES1 3345/4885APAF1 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.